# Traumatic Optic Neuropathy Treatment Trial 2

> **NCT03308448** · PHASE3 · COMPLETED · sponsor: **Iran University of Medical Sciences** · enrollment: 93 (actual)

## Conditions studied

- Traumatic Optic Neuropathy

## Interventions

- **DRUG:** Recombinant human erythropoietin

## Key facts

- **NCT ID:** NCT03308448
- **Lead sponsor:** Iran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-06
- **Primary completion:** 2022-08-06
- **Final completion:** 2023-03-02
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03308448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03308448, "Traumatic Optic Neuropathy Treatment Trial 2". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03308448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*